Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxcarbazepine for Bipolar Disorder
NCT00154323Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2003
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of oxcarbazepine in bipolar disorder (BD) (2 arms), sponsored by Novartis. Primary endpoint: Duration of remission. Started Jan 2003; status: completed.
02
Drugs
oxcarbazepine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00154323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00154323.